

Investor Presentation

1H25 Report

Prepared in accordance with China Accounting Standards

Contents

①

**Performance Highlights and
Financial Review**

②

Innovation and Internationalization

③

Pharmaceutical

④

Med Tech

⑤

Healthcare Services

⑥

Appendix



Performance Highlights and Financial Review

1H25 Financial Review (1/2)

Revenue

RMB **19,514** million
(-4.63%YoY)

- Revenue decrease due to renewal of VBP and regional VBP
- Focusing on innovative drugs and high-value devices, promoting the transformation of product portfolio and strategy

Innovative Drugs Revenue

> RMB **4,300** million
(+14.26%YoY)

R&D Expense

RMB **2,584** million
(-5.59%YoY)

- Increasing R&D investment in innovative drugs, while optimizing the investment in generic drugs
- Optimizing the innovative R&D system, focusing on key pipelines, and improving efficiency through R&D system integration
- Practicing an open R&D model by incubating and investing in innovative R&D projects through industry funds and other means to ensure the sustainability of innovation

Net Operating Cash Flow

RMB **2,134** million
(+11.90%YoY)

- Enhancing supply chain management and operational efficiency
- Continuously optimizing asset structure and accelerating cash return
- Since 2025, the total contracted disposal amount has exceeded RMB2,000 million

Net Profit Attributable to Shareholders

RMB **1,702** million
(+38.96%YoY)

- Gain on sale of equity in United Family Healthcare and other non-core assets
- Net Profit after One-off Gain reached RMB 961 million (-23.39% YoY) due to (1) Revenue declined YoY; (2) Fosun Kairos, consolidated as a wholly-owned subsidiary since 4Q24, remained in investment stage, increasing attributable loss; (3) Some associates reported lower earnings YoY
- Continued lean management to improve quality and efficiency, 2Q25 Net Profit after One-off Gain was RMB 550 million, + RMB 140 million QoQ (+34.15%QoQ)

1H25 Financial Review (2/2)

Expense Structure (RMB million)	1H25	1H24
Revenue	19,514	20,463
Gross Profit	9,391	10,000
Gross Margin	48.1%	48.9%
Selling and Distribution	4,211	4,266
Ratio	21.6%	20.8%
Gross Margin minus Selling and Distribution Expense Ratio	26.7%	28.0%
Administrative	2,028	2,064
Ratio	10.4%	10.1%
R&D	1,717	1,862
Ratio	8.8%	9.1%
Finance	640	589
Ratio	3.3%	2.9%

Key Influencing Factors

- Revenue decreased YoY with a corresponding decrease in gross profit due to renewal of VBP and regional VBP
- Revenue from innovative drugs maintained solid growth
- Continued to strengthen control over selling expenses through refined management and optimized resource allocation
- Maintaining investment in market development and sales teams for newly launched products.
- Control of expenses, improvement of human efficiency and reduction of administrative expenses
- Maintaining a relatively stable R&D intensity, focusing on advantageous pipelines, continuously optimizing the innovation R&D system, and improving R&D efficiency
- Practicing an open R&D model by incubating and investing in R&D projects through industry funds and other means to ensure the sustainability of innovation
- Foreign exchange losses increased YoY, while interest expenses decreased YoY
- Debt structure improved, with a significant reduction in the proportion of high-interest foreign currency debt

Key Indicators

	1H25	1H24
Cash and Bank Balances (RMB million)	12,959	14,080
Net Asset Attributable to Shareholders (RMB million)	47,397	46,967
Current Ratio	0.95	0.93
Quick Ratio	0.77	0.73
Debt-to-Asset Ratio	49.2%	49.1%

1H25 Performance Highlights

Launched Key Products



Luvometinib Tablets (MEK1/2 inhibitor)

- May - Approved by NMPA for treatment of (1) adult patients with Langerhans cell histiocytosis (LCH) and histiocytic neoplasms; (2) pediatric and adolescent patients aged 2 years and above with symptomatic, inoperable plexiform neurofibromas (PN) associated with type 1 neurofibroma (NF1)



Serplulimab Injection (PD-1)

- Feb - Receives the EMA approval for the treatment of ES-SCLC
- Approved in Singapore, Malaysia, the UK, and India in June, with approvals now granted in over 30 countries and regions



Fovinacilic Citrate Capsules (CDK4/6 inhibitor)

- May - Approved by NMPA for treatment of HR-positive, HER2-negative breast cancer



Tenapanor Hydrochloride Tablets

- Feb - Approved by NMPA for the control of serum phosphorus levels in adult dialysis patients with chronic kidney disease

Key Filings & Clinical Progress

Filings

Fovinacilic Citrate Capsules (CDK4/6 Inhibitor)

- Jan - NDA accepted by NMPA for 1L breast cancer

Foritinib (ALK/ROS1)

- Mar - NDA accepted by NMPA for ALK+ NSCLC

Fortacin Spray

- Mar - NDA accepted by NMPA for primary premature ejaculation

HLX11 (HER2)

- BLA was accepted by the FDA in Jan., MAA was accepted by the EMA in March, for the treatment of HER2+ breast cancer

HLX14 (RANKL)

- July - Received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) on marketing authorization*

Clinical Progress

Luvometinib Tablets (MEK1/2 inhibitor)

- July - Ph3 clinical trial initiated in China for pediatric low-grade glioma*

FXS6837

- The indications in the field of immunomodulation entered Ph2 clinical trials in January and March, respectively

XH-S004 (DPP1)

- Apr - Entered Ph2 for NCFBE
- May - Entered Ph1b for COPD*

HLX22 (HER2)

- Ph3 MRCT initiated for HLX22 combined with Trastuzumab + chemotherapy as 1L treatment for advanced gastric cancer; first patient dosed in Japan in March; first patient dosed in the U.S. in July*; received Orphan Drug Designation from FDA and EMA in March and May respectively
- Apr - First patient dosed in China in Ph2 trial combining HLX22 with Trastuzumab Deruxtecan for breast cancer

HLX43 (PD-L1 ADC)

- Multiple Ph2 trials ongoing in China as monotherapy or combined with Serplulimab (PD-1) for various solid tumors
- First patients already dosed in Ph2 trials for relapsed/metastatic ESCC and advanced NSCLC

Note#: License-in products

Note*: Subsequent events

Note†: Include NSCLC, TSCC, HCC, ESCC, HNSCC, CC, NPC, and others



Innovation and Internationalization

Innovative Pipeline & System Development

Core Therapeutic Areas

Oncology



Solid Tumor

Antibody

- HLX-10 (PD-1)
- HLX-22 (HER-2)

ADC

- FS-1502 (HER-2 ADC)
- HLX-43 (PD-L1 ADC)
- HLX-42 (EGFR ADC)

Small Molecule

- XS-02 (CHK1)
- XS-03 (PLK1)
- FCN-159 (MEK1/2)
- FCN-437α (CDK4/6)



Heme

Antibody

- Rituximab (CD20)
- HLX-15 (CD38)

Cell Therapy

- FKC-876 (CD19-CAR-T)
- FKC-889 (CD19-CAR-T)
- GCK-01 (CAR-NK)

Small Molecule

- XS-04 (IRAK4/BTK)

Non-oncology



Immunization

Cellular Therapy

- Rituximab (CD20)
- Adalimumab (TNF-α)

Cell Therapy

- FKC-289

Small Molecule

- FXS6837



CNS

Small Molecule

- ET-26 (GABA receptor)
- Opicapone (COMT)
- AR1001 (PDE5)



Chronic Disease

Antibody

- HLX14 (RANKL)

Small Molecule

- XH-S004 (DPP1)

Vaccine



Vaccine

Inactivated and Live Attenuated Vaccine

- Rabies Vaccine, Freeze-dried
- Varicella Vaccine
- Cell-based flu vaccine

Polyvalent Conjugate Vaccine

- PCV13
- PCV24
- MCV4

Recombinant Vaccine (Insect Cell)

- Shingles Vaccine

Licensing & Global Operations

Licensing

	Licensing Product/Pipeline	Target	Partner	Regions	Down Payment	Potential Total Amount
Out	XH-S004	DPP1	Expedition	Global (excluding Mainland China, Hong Kong and Macau)	USD 17 million	USD 645 million
	FXS6837	-	Sitala	Global (excluding Mainland China, Hong Kong, Macau and Taiwan)	USD 25 million	USD 670 million
	HLX15	CD38	Dr.Reddy's	United States, Europe	USD 33 million	USD 130 million
	HLX13	CTLA-4	Sandoz	United States, Europe, Japan, etc.	USD 31 million	> USD 300 million
	Serplulimab	PD-1	Alvogen	South Korea	USD 5 million	USD 112 million
In	AR1001	PDE5	NEUCO UNITED	Mainland China, Hong Kong and Macau	RMB 40 million	RMB 110 million
	FXB0871	PD-1/IL-2	Teva	Mainland China, Hong Kong, Macau, Taiwan and selected Southeast Asian countries	-	-
	HLX701	CD47	HanchorBio	China (excluding Taiwan), Southeast Asia and selected countries in MENA	USD 10 million	USD 192 million

Mature

U.S.

- **Generic Drugs:** maturing team with 34 launched products
- **Innovative Drugs:**
 - ◆ Clinical trials of Serplulimab (PD-1), HLX11 and HLX22
 - ◆ Team covering medical affairs, market access, sales, etc., supporting the U.S. commercialization of Serplulimab (PD-1)

EU

- **Innovative Drugs:**
 - ◆ Serplulimab approved by the EMA in Feb.
 - ◆ Ph3 MRCT of HLX22 for gastric cancer; granted Orphan Drug Designation in May
- **Biosimilars:** filings of HLX11 and HLX14

Japan

- In March, the first patient dosing of the Ph3 MRCT of HLX22 for 1L GC was completed
- In June, the first patient enrollment of the bridging trial of Serplulimab (PD-1) for SCLC was completed

Emerging

India

Gland Pharma

- India's first injectable manufacturer approved by the U.S. FDA
- Established localized manufacturing capabilities in Europe through its holding subsidiary Cenexi

Africa

- Marketing across more than 40 countries and regions
- Continuously constructing the Côte d'Ivoire Industrial Park to achieve localized manufacture and distribution

South East Asia

- Established Nanning pharmaceutical and medical device sales platform in February to advancing registration and commercialization capabilities
- In June, Serplulimab (PD-1) received marketing approval in Singapore and Malaysia

Middle East

- In April, collaborated with Fakeeh Care Group to promote the launch of innovative therapeutic products in Saudi Arabia



Localization of Innovation in China

Domestic Cultivation



FOSUN KAIROS 复星凯瑞

- Increased holdings in Fosun Kairos to **100%** in September 2024
- Strategically increasing investment** in core assets and core R&D technology platforms
- Keep the long-term strategic collaboration with Kite Pharma through **licensing agreements**

- China's first approved CAR-T therapy, Yikaida (Axicabtagene Ciloleuceel Injection) received approval for a **second-line indication** in June 2023.
- Included in over **110** commercial insurances and over **90** citizen insurances; over **200** treatment centers covering more than **28** provinces and cities
- Introduced **value-based payment**, exploring innovative payment models for high-value innovative therapy in January 2024
- Passed the **preliminary formal review** for inclusion in the newly established **Commercial Health Insurance Innovative Drug Directory** in August 2025

JV

INTUITIVE FOSUN 直观复星

- In 1H25, **29** Da Vinci surgical robotic systems were newly installed in Mainland China and Macao
- Da Vinci systems had been installed in over **370 hospitals**, with cumulative installations exceeding **450 systems** and **more than 760,000 patients** served
- Leveraging Hainan's "**licensed medical devices**" permission, the Da Vinci SP surgical system has been broadly applied across multiple disciplines at Ruijin Hainan Hospital, with real-world study reports in several specialties, supporting the **acceleration of formal registration and approval**
- 2** additional Ion Robotic Bronchoscopy were installed in China, bringing the cumulative total to **6** systems, having served over 200 patients

FOSUN INSIGHTEC 复星医视特

- Established a JV in China with **Insightec** in February 2024
- "Focused Ultrasound Platform"**— new model registration and indication expansion progressing steadily; clinical value and recognition rising, adoption accelerating in China
- Utilizing MRI-guided imaging, the system enables **non-invasive treatment of various neurological disorders** with millimeter-level precision, representing cutting-edge technology in non-invasive transcranial therapy
- Aims to treat patients with **Parkinson's diseases and essential tremor**

Digitalization & AI Empowering Growth

- Continuously deepening its **digital and AI strategic initiatives**, the company has progressively established a comprehensive digital and intelligent ecosystem spanning **R&D, operations, and product applications**. Fosun Pharma stands among China's earliest pharmaceutical enterprises to **deploy large language models (LLMs)** such as GPT-4o and DeepSeek, outline an AI-driven pharmaceutical blueprint, and launch AI application tools. It was also recognized as one of the **“Top 10 Forbes China AI Innovation Application Enterprises for 2025.”**

Pharmaceuticals

- PharmAID decision intelligence platform**
 - Empowering drug discovery through intelligent solutions to build high-value pipelines and enhance R&D efficiency
 - Integrate multiple **global clinical information and pipeline databases**; Data updates can be achieved within **T+1 days**
 - Medical and health content generation accuracy **outperforms** general-purpose large models
 - Information extraction efficiency **increased by 50%**
- R&D computing system**
 - By relying on toolkits such as DTC-Fold structure prediction, DTC-BioGPT, and CADD molecular property prediction and safety evaluation, **molecular design efficiency has been increased by 50%**, strongly supporting the reserve of early R&D pipelines and the transformation of research results
- HenliSciAI platform of the subsidiary Shanghai Henlius**
 - Assist in **identifying new drug targets**, which **significantly enhances the efficiency of drug discovery**
- External Collaboration**
 - Collaborates with **Zheyuan Bio** to actively explore the application of digital twin in clinical trials

Med Tech

- Sisram Medical**
 - launched **Alma IQ™, a smart skin analysis and consultation solution**, to the global market
 - introduced **Universkin by Alma, a pioneering AI-powered personalized medical and skincare system**. By professional AI-based analysis, the system tailors skincare formulations based on the users' individual skin types and aesthetic preferences
- Fosun Xingmai**, a subsidiary of the Company, focused on smart healthcare innovation, emerging as one of China's few integrated **AI-powered medical service solution providers with multi-department coverage**
- Futuo Zhida**, focused on the innovation in the field of AI surgical navigation and introduced a 3A surgical solution based on core technologies of **AI (Artificial Intelligence), AR (Augmented Reality), and AT (Advanced Tools)**. This solution combines AR navigation with minimally invasive surgery, and utilizes computer vision-based monocular tracking and AR display to **achieve precision targeting and optimize intraoperative workflows**, maximizing healthy tissue preservation while improving surgical efficiency and safety.

Health Care Service

- AI-powered outbound calls and the “Star Doctor” mini-program, it provides patients with **intelligent follow-up, triage, and report interpretation services**, covering over 100,000 people.

Equity Incentives Guide Performance

Share Repurchases Support Market Confidence

- Through long-term incentive mechanisms, the Company [attracts and retains top talent](#), motivates employees, and [aligns the interests](#) of shareholders, the Company, and the team, focusing collectively on [long-term value creation](#)

RMB 1 billion	Weight	2025	2026	2027	CAGR
Net Profit Attributable to Shareholders	60%	3.32	3.96	4.77	~20%
Innovative Drug Revenue	40%	9.36	11.23	13.48	

	A-Share Equity Incentive Plan	H-Share Equity Incentive Plan
Instrument	A-Share Options	RSU
Share Source	Company Treasury Shares	
Total Size	5,726,100 options; representing 0.2144% of total share capital and 0.2729% of total A-shares	13,370,500 RSUs, representing 0.5007% of total share capital and 2.4716% of total H-shares
Eligible Participants	Directors, senior executives, mid-level managers, and key employees	
Pricing (First Grant)	RMB 27.93 per share	RMB 1.00 per share
Validity Period	Up to 60 months	60 months (from plan adoption date)

Fosun Pharma is confident in its long-term development, firmly protecting investors' interests, and actively repurchasing shares to reinforce market confidence.

2024 Share Repurchases				2025 Share Repurchases (1/22-7/21)			
	Number of Shares (million)	Total Amount	Average Price		Number of Shares (million)	Total Amount	Average Price
A share	5.68	RMB 127 million	RMB 22.31 per share	A share	14.23	RMB 348 million	RMB 24.48 per share
H share	7.56	HKD 97 million	HKD 12.79 per share	H share	3.41	HKD 48 million	HKD 14.03 per share

Sustainable Development

- Continuously Enhancing ESG Governance to Support Long-term Sustainable Development
- Disclosed ESG Practices and Achievements for **17** Consecutive Years
- The **2024 ESG and Sustainability Report** complies with the latest disclosure requirements of both A-share and H-share markets

MSCI ESG Rating

AA

Hang Seng ESG Rating

A-



2025 Fortune China
ESG Impact List

2024 China ESG 50 List
(Forbes China)



Environmental

- **Senior executive compensation is linked to environmental performance**, with a weighting of **no less than 10%**
- **RMB 110 million** invested in environmental protection initiatives in 2024
- **83%** of manufacturing subsidiaries are certified under the **ISO 14001** Environmental Management System
- In 2024, energy-saving measures—including electricity, natural gas, and purchased steam—reduced carbon emissions by 10,196 tons. Procurement of over 19.25 million kWh of green electricity further reduced emissions by 10,332 tons
- In 2024, total in-house photovoltaic (PV) power generation exceeded **14.58 million kWh**, representing approximately a **fourfold** YoY increase
- Steady progress made toward multiple pollutant emission targets

Social

- Approved **5** rare disease indications; **9** rare disease indications are under development
- **Over 84 million** severe malaria patients globally have been treated with Artesunate for Injection; seasonal malaria chemoprevention programs have benefited **over 324 million** children in Africa; plans to donate anti-malarial drugs worth **RMB 10 million** to Africa over three years; in 2025, **900,000 doses donated**
- The Côte d'Ivoire manufacturing facility under construction is expected to reach an annual capacity of **5 billion tablets** and create **nearly 1,000** local jobs
- In 2024, **over 2,500** CME (Continuous Medical Education) training sessions were conducted for local healthcare professionals in Africa, with **more than 41,000 attendees**
- Joined **Pharmaceutical Supply Chain Initiative (PSCI)**
- **ISO 9001** quality management system coverage **exceeds 90%**
- Annual green supply chain **audits** conducted for suppliers
- An equitable and inclusive workplace, with female employees accounting for **50.3%**

Governance

- **A professionally diverse Board of Directors**: the company has adopted a Board Diversity Policy; board members are experts from various industries and sectors; independent directors comprise 33% of the board
- **Top-down ESG governance structure**: the Company has established an ESG governance framework consisting of the Board and its ESG Committee, ESG Management Committee, and ESG Working Groups
- **Senior executive compensation is linked to ESG performance**, with a weighting of **no less than 10%**
- The business ethics audit plan **covers all operational sites every 3 years**
- Responsible marketing audits cover all **external marketing activities**
- **Annual training** on business ethics and responsible marketing is provided to **all personnel**



Pharmaceutical

An Innovation-driven Pharmaceutical and Healthcare Industry Group



R&D Innovation

- 4 core technology platforms
- 3 core therapeutic areas
- 3,000+ R&D staff
- 70+ in-progress innovative drug projects (by indication)

Manufacturing System

- Vertical integration of the chemical API and formulation, clustering to the advantageous manufacturing capacity
- Commercialized production capacity of 48,000L for biologics
- ~70 official inspections
- 13 manufacturing lines have passed GMP certification of the U.S. FDA, EU and other markets




Commercialization System

- Professionalization, branding, digitalization, compliance
- ~5,000 commercialization staff in China
- 1,000+ overseas commercialization staff
- Continuous optimization of marketing compliance management system

Pharma - Performance


Segment Revenue¹

RMB million




R&D Expenditure & Expense

RMB million




Segment Results²

RMB million




Pharma R&D Expenditure and Expense

RMB million



Segment Profit

RMB million



- 1H25 Pharma R&D expenditure was **RMB 2,295 million** accounts for over **89%** of the total R&D expenditure and **16.51%** of the Pharma revenue; Pharma R&D expense was **RMB1,469 million**, accounts for **10.57%** of the Pharma revenue; R&D expenses decreased YoY, primarily due to the R&D system optimization, efficiency improvements, and pipeline prioritization
- Practicing an open R&D model by incubating and investing in innovative R&D projects through **industry funds** and other means to ensure the **sustainability** of innovation
- 80+** in-progress innovative drug and biosimilar projects (by indication)
- Filed **142** Pharma patents, including 3 U.S. applications, 3 PCT applications; granted **27** invention patents in 1H25

Note¹: Revenue decrease due to renewal of VBP and regional VBP

Note²: Segment results are obtained as segment revenue less costs of sales, selling and distribution expenses, administrative expenses and R&D expenses

Pharma Key Progress - Serplulimab Injection (PD-1)

The first PD-1 inhibitor approved for 1L SCLC



1H25 Revenue

RMB **598** million



Approved Indications in Chinese Mainland

- sqNSCLC
- ES-SCLC
- ESCC
- nsqNSCLC

Overseas Progress

- Approved by the EMA in Feb. 2025
- Approved in June in Singapore, Malaysia, the UK, and India; now approved in over 30 countries and regions
- Initiated ES-SCLC head-to-head bridging in the U.S.
- Initiated ES-SCLC bridging clinical trial in Japan in June

Outstanding Results

- Serplulimab + chemo (ES-SCLC) real world, global, multi-center data was released in 2024 WCLC. As the data shown, the median rwPFS was 9.1 months (95% CI: 8.1-9.7), with a 1-year rwPFS rate of 34.6%, surpassing the 1-year PFS rate of 28.2% reported in the ASTRUM-005 study. Besides, the 2-year rwPFS rate was shown to be 11.3%.
- The clinical data have been published in world's top medical journals including The Journal of the American Medical Association (JAMA), Nature Medicine and British Journal of Cancer

Quick Market Access and Accelerated Market Penetration

- A commercialization team of approximately 600 people has completed territory segmentation, demonstrating strong professional communication skills and extensive oncology promotion experience.
- Establishing an innovative pharmaceutical team in the U.S. to support the U.S. commercialization
- Granted the exclusive development and commercialization rights in agreed European Countries and India to Intas with upfront payments up to €42 million in October 2023
- Granted the exclusive commercialization and semi-exclusive development rights in South Korea to Alvogen, with an upfront payment of USD 5 million and a potential total value of up to USD 112 million; in March, Serplulimab for the treatment of ES-SCLC received orphan drug designation from the South Korean Ministry of Food and Drug Safety (MFDS)

Pharma Key Progress - Axicabtagene Ciloleucel Injection

- Axicabtagene Ciloleucel is an innovative **one-time treatment** cell therapy, delivering **lasting relief to patients** and significantly **improving their long-term survival**
- A study published in the **American Society for Transplantation and Cellular Therapy (ASTCT)** compared **Axicabtagene Ciloleucel 2L r/r LBCL treatment with standard treatment**. The study shows that treatment with Axicabtagene Ciloleucel can improve **patient survival rates**, **extend progression-free survival**, thereby **reducing the burden on patients**, **conserving healthcare resources**, and **offering superior cost-effectiveness** compared to standard treatment in terms of **pharmacoeconomics**

Indication Expansion

- Approved **2L r/r LBCL** in June 2023
- First** CAR-T cell therapy product approved in China

Expanding market potential

- LBCL is the most common subtype of NHL. LBCL accounts for **45.8%** of all NHL in China, **over 40,000 new cases** of LBCL annually, and nearly **13,000 cases are considered** refractory or have experienced a relapse

Efficacy¹

	3L		2L
	ZUMA-1	China RWS	ZUMA-7
bORR	82%	83%	83%
bCR	58%	58%	65%
OS	43% (5 years)	84% (1year)	55% (4year)
<ul style="list-style-type: none"> The r/r NHL real-world efficacy of multicenter clinical trial in China aligns with global data, with 12-month overall survival rate at 84.3%, bORR at 83.2%, bCR at 58.4%, and a better safety result 			

Commercialization

- Treated over **1000 patients** with **over 200 treatment centers** covering more than **28 provinces and cities**; with 10,000 m² GMP commercial manufacturing facility
- Diversified payment methods: included in **over 90** commercial insurances and **over 110 citizen insurances**
- Introduced **Pay for Performance (PFP)**, exploring innovative payment models for high-value treatment in January 2024
- Passed the preliminary formal review** for inclusion in the newly established **Commercial Health Insurance Innovative Drug Directory** in August 2025

Product Pipeline

- The **3rd indication r/r INHL**, including **FL and MZL**, is in the **bridging clinical trial stage** in China and has been granted with **Breakthrough Therapeutic Designation** by the NMPA
- FDA approved Tecartus (Brexucabtagene Autoleucel) for the treatment of **r/r MCL and r/r ALL** are both in the **bridging clinical trial stage** in China

Note¹: Axicabtagene Ciloleucel is recommended by domestic and overseas authoritative guidelines. Treatment on patients with **2L+ DLBCL** is recommended by National Comprehensive Cancer Network (NCCN) Guidelines in the U.S., National Health Commission Guidelines, Chinese Medical Association Guidelines and Chinese Society of Clinical Oncology (CSCO) Guidelines. Treatment on patients with **2L DLBCL** received category I recommendation from the NCCN Guidelines in the U.S. and from the CSCO

Pharma Key Progress - Potential Drivers



Keverprazan Hydrochloride

- Rapid, stable, and long-lasting effects
- In the Ph3 study, the mucosal healing rate in the treatment of RE reached **95.8%** in 8 weeks; the DU healing rate reached **94.4%** in 6 weeks
- Implemented the NRDL



Telpegfilgrastim Injection

- Long-lasting recombinant human granulocyte colony-stimulating factor product
- New PEG structure, **longer half-life and lower dosage**
- Restore the number of neutrophils in peripheral blood to reduce the incidence of infection in tumor patients after chemotherapy; **the incidence of all adverse reactions is less than 10%**, which is good in terms of safety and tolerability
- Implemented the NRDL



Sacubitril Valsartan Sodium Tablets

- An innovative crystalline form to treat heart failure and hypertension
- Can be stored sealed up to 30°C and is **more stable in high humidity environments**
- Reduce the risk of composite outcome of cardiovascular mortality or heart failure hospitalization by **20%** and reduce the risk of rehospitalization for heart failure by **21%** in patients with HFrEF
- Implemented the NRDL



Netupitant and Palonosetron Hydrochloride Capsules

- The world's first dual-channel antiemetic drug
- Blocking NK-1 receptor and 5-HT3 receptor simultaneously; the **half-life is up to 96 hours**
- The non-salvage treatment rate for CINV is as high as 96.6%, the non-salvage treatment rate for delayed CINV is as high as 97.6%, and **the daily non-significant nausea rate is over 86%**
- Implemented the NRDL



Etelcalcetide Hydrochloride Injection

- new generation of calcimimetic
- Long-lasting; **half-life 3-4 days**
- The Ph3 study shows reduced PTH, FGF23 and BTMs
- Intravenous administration three times a week after dialysis is better tolerated by patients and **improves patient compliance and ease of administration**



Neratinib

- Novel, orally administered, potent and irreversible small-molecule pan-HER (TKI)
- HER2+ BC patients with large primary tumors, positive lymph nodes, and incomplete pathological remission after neoadjuvant therapy can obtain the **significant reduction of the risk of recurrence** if they continue the treatment with neratinib as an intensified adjuvant therapy
- Implemented the NRDL

Pharma Key Progress - Core Products & Pipelines

Luvometinib Tablets

- Self-developed innovative small-molecule MEK1/2 inhibitor
- **Mechanism:** Inhibits tumor proliferation driven by abnormal RAS pathway
- **Adult LCH and histiocytic tumors** (Ph2, median follow-up 16.2 months):
 - **Significant efficacy:** IRC-assessed PET Response Criteria (PRC) **ORR = 82.8%**
 - **Rapid response:** median time to response (mTTR) = **2.9 months**
- **Pediatric and adolescent NF1 patients with symptomatic inoperable PN** (Ph2, median follow-up 15.1 months):
 - **Significant benefit and rapid response:** **ORR = 60.5%, mTTR = 4.7 months**
 - Among 14 children with baseline tumor-related pain, **78.6% achieved complete pain resolution**



Fovinaciclilb Citrate Capsules

- Self-developed innovative small-molecule CDK4/6 inhibitor
- **Mechanism:** Selectively inhibits CDK4/6-Cyclin D kinase activity, preventing Rb protein phosphorylation, blocking cell cycle progression from G1 to S phase, and arresting tumor cells in G1 phase to inhibit proliferation
- **Clinical Results:** 2L HR-positive, HER2-negative recurrent or metastatic breast cancer
 - **Significant survival benefit:** **More than doubled median PFS (PFS HR: 0.484)**
 - **Broad efficacy:** Suitable for premenopausal, perimenopausal, and postmenopausal advanced breast cancer, with especially strong efficacy in premenopausal patients
 - **Favorable safety profile:** Low gastrointestinal adverse events, minimal impact on quality of life, food-independent dosing, suitable for long-term treatment

Launched

R&D
Pipeline

Foritinib (SAF-189s)

- Next-generation, potent ALK/ROS1 inhibitor with CNS penetration
- **Mechanism:** Competitively binds to the ATP-binding pocket of ALK/ROS1 kinases, blocking ATP binding and kinase phosphorylation, thereby inhibiting kinase activity and suppressing tumor cell proliferation, survival, and metastasis
- **Clinical Results:** ALK-positive non-small cell lung cancer (NSCLC)
 - **Significant improvement in PFS and OS:** PFS HR 0.23; OS HR 0.60
 - **Marked reduction in CNS progression risk:** Median CNS-TTP in the crizotinib group was 19.32 months, while the median CNS-TTP for Furuitinib has not yet been reached (**HR 0.04**, 95% CI 0.01–0.14)
 - **High CNS penetration:** Among patients with baseline brain metastases, **intracranial ORR reached 100%** in the Furuitinib group versus 50% in the crizotinib group

AR1001 (PDE5 Inhibitor)#

- Potent, highly selective PDE5 inhibitor
- Rights for Mainland China and Hong Kong/Macau in-licensed from NEUCO UNITED, with an upfront payment of RMB 40 million in August
- **Mechanism:** Clears AD-related amyloid plaques, inhibits abnormal Tau phosphorylation, suppresses inflammation, and provides neuroprotection
- **Clinical Results:** Mild-to-moderate Alzheimer's Disease
 - **Efficacy Data:** In mild AD patients receiving AR1001 only, the 10 mg group improved by 2.4 points from baseline (15.1%), while the 30 mg group improved by 8.7 points (46.3%, P=0.001)

Pharma Key Progress - Core Antibody Pipelines

HLX22

-Innovative HER2 mAb

- Mechanism:** Targets a distinct epitope on HER2 domain IV; when combined with trastuzumab, **enhances HER2 internalization by 40–80%**
- Clinical Study:** Ph2 trial (HLX22-GC-201) evaluating HLX22 + trastuzumab + XELOX as 1L treatment for HER2-positive locally advanced or metastatic gastric/gastroesophageal junction (G/GEJ) cancer; results selected as a poster presentation at 2025 ASCO GI
- Key Findings:** Adding HLX22 to trastuzumab + chemotherapy improved survival and antitumor response in 1L HER2-positive G/GEJ cancer patients, with manageable safety profile

	HLX22 group (n = 31)	Placebo group (n = 31)
mPFS, months (95% CI)	NR (23.5–NE)	8.3 (5.7–12.7)
HR (95% CI)	0.2 (0.06–0.45)	p<0.0001
12-month PFS rate (95% CI)	73.8 (50.3–87.4)	34.2 (12.0–58.1)
24-month PFS rate (95% CI)	61.5 (30.4–82.0)	11.4 (0.8–38.1)
mOS, months (95% CI)	NR (23.5–NE)	22.0 (10.6–NE)
HR (95% CI)	0.5 (0.20–1.21)	p=0.1174

Clinical Progress

- HLX22-GC-301:** First patient dosed in the U.S.
 - Combined with Trastuzumab and chemotherapy as 1L treatment for HER2-positive advanced gastric cancer
 - Head-to-head comparison with first-line standard therapy (Trastuzumab + chemotherapy ± Pembrolizumab)
- HLX22-BC-201:** First patient dosed in China
 - Combined with Trastuzumab deruxtecan for HER2-low, HR-positive breast cancer

HLX43

-An anti-PD-L1 ADC with TMALIN* linker and TOPO1i Payload

Ph1 Clinical Data

Table 2. Efficacy in efficacy-evaluable patients per RECIST v1.1^a

	Phase 1a (n = 19)	Phase 1b 2.0 mg/kg (n = 21)
CR, n (%)	0	0
PR, n (%)	7 (36.8)	8 (38.1)
SD, n (%)	7 (36.8)	9 (42.9)
PD, n (%)	4 (21.1)	4 (19.0)
NE, n (%)	1 (5.3)	0
ORR, % (95% CI)	36.8 (16.3–61.6)	38.1 (18.1–61.6)
DCR, % (95% CI)	73.7 (48.8–90.9)	81.0 (58.1–94.6)
mDOR, months (95% CI)	7.2 (1.4–NE)	NR (1.4–NE)
mPFS, months (95% CI)	4.2 (2.7–8.4)	5.4 (4.0–6.3)
mOS, months (95% CI)	8.9 (6.0–NE)	NR (6.7–NE)

Table 3. Subgroup analysis of tumor response in the phase 1b 2.0 mg/kg cohort per RECIST v1.1^a

	ORR % (95% CI)	DCR % (95% CI)
NSCLC subtype		
Squamous (n = 15)	40.0 (16.3–67.7)	73.3 (44.9–92.2)
Nonsquamous (n = 6)	33.3 (4.3–77.7)	100 (54.1–100)
Used docetaxel		
Yes (n = 9)	33.3 (7.5–70.1)	77.8 (40.0–97.2)
No (n = 12)	41.7 (15.2–72.3)	83.3 (51.6–97.9)
Brain metastasis		
Yes (n = 6)	33.3 (4.3–77.7)	100 (54.1–100)
No (n = 15)	40.0 (16.3–67.7)	73.3 (44.9–92.2)
Liver metastasis		
Yes (n = 3)	33.3 (0.8–90.6)	66.7 (9.4–99.2)
No (n = 18)	38.9 (17.3–64.3)	83.3 (58.6–96.4)
PD-L1 expression		
CPS ≥ 1 (n = 16)	37.5 (15.2–64.6)	81.3 (54.4–96.0)
CPS < 1 (n = 5)	40.0 (5.3–85.3)	80.0 (28.4–99.5)

^a Unconfirmed tumor response assessed by investigator. CI, confidence interval; CR, complete response; DCR, disease control rate; mDOR, median duration of response; mPFS, median progression-free survival; mOS, median overall survival; NE, not evaluable; NR, not reached; NSCLC, non-small cell lung cancer; ORR, objective response rate; PD, progressive disease; PD-L1, programmed death-ligand 1; PR, partial response; SD, stable disease.

Clinical Progress:

- Ph2 trials for **recurrent/metastatic esophageal squamous cell carcinoma and advanced non-small cell lung cancer (NSCLC)** have both dosed their first patients
- Multiple clinical programs targeting various solid tumors, including NSCLC, thymic squamous carcinoma, hepatocellular carcinoma, esophageal squamous carcinoma, head and neck squamous carcinoma, cervical cancer, and nasopharyngeal carcinoma

Note: CI, confidence interval; HR, hazard ratio; NE, not evaluable; NR, not reached; PFS, progression-free survival; XELOX, oxaliplatin+capecitabine






Med Tech

Med Tech - Performance


Segment Revenue¹

(RMB million)




Segment Result^{2/3}

(RMB million)



Segment Profit⁴

(RMB million)



Aesthetic Field

- Sisram focuses on cultivating a "dual-engine" strategy of "EBD + Injectables" to accelerate business focus and growth

Respiratory Care

- Breas has steadily increased the operating revenue, net profit and operating cash flow, continued growth momentum in key markets such as the U.S., the U.K., and Japan

Professional Medical Device & Consumables

- The da Vinci Xi Surgical Robotic System maintains industry-leading tender success rate and market dominance
- JediVision® lung nodule marker placement and localization device, independently developed by Futuo Zhida, has been approved as a Class III medical device

Fosun Diagnosis

- In August, Fosun Diagnostics received approvals for two products: China's first and currently only home testing kit for COVID-19/Influenza A&B antigens, and the first approved product under Fosun Diagnostics's Respiratory Infection Syndrome multiplex nucleic acid detection solution — the COVID-19/Influenza A&B nucleic acid test kit (fluorescent PCR)
- The fully automated high-speed chemistry immunoassay instrument completed follow-up validation and optimization upgrades
- Collaborated with Siemens Healthineers and registered 16 customized biochemical reagents and 1 quality control product

Note¹: Due to geopolitical impacts, shipment restrictions delayed part of the revenue recognition to the second half, leading to lower sales in North America and other regions

Note²: Segment results are obtained as segment revenue less costs of sales, selling and distribution expenses, administrative expenses and R&D expenses


Note³: Improved gross margin and operating efficiency in the Med Tech reduced losses YoY

Note⁴: Increased investment income from joint ventures and divestment of non-core assets drove profit growth

Medical Devices - Sisram Medical

- Sisram, dedicated to medical aesthetics, advancing dual-engine strategy of “energy-based devices + injectables”
- Established 12 direct sales offices worldwide with a marketing network covering over 110 countries and regions

Financial Performance



- Faced challenges in North America due to the macroeconomic environment and temporary supply chain disruptions caused by geopolitical tensions
- Excluding North America, international markets recorded 7.1% YoY revenue growth, with Asia-Pacific revenue reaching USD 65.8 million, up 17.6% YoY

Net Profit

- Decline in revenue from North America
- Strategic product mix shift toward core, professional-grade, and precision premium products, which carry higher material costs due to advanced specifications
- Flexible adjustment of operating cost structure to adapt to market changes

Key Progress in EBD

- Progressing market entry of two EBD solutions in China



Soprano Titanium



Alma Harmony



Alma PrimeX



BeautiFill by Lipolife



Opus



Alma TED



Alma DUO



Alma Hybrid

Complementary Solutions

- Launched the pioneering diagnostic concept Alma IQ™, an intelligent skin analysis and consultation solution
- Launched Unverskin by Alma, an AI-based personalized solution offering customized medical-grade skincare products

Key Progress in Injectable

- Skin bio-remodeling therapy Profhilo® maintained strong growth momentum in Thailand
- In collaboration with Prollenium, the Revanesse® filler portfolio achieved sales in the UK and established local sales teams in Germany and Australia to drive market expansion
- Simultaneously introduced the first-of-its-kind combination of HA & bio-stimulator Hallura® and advanced its commercialization in strategic markets
- Advancing commercialization preparations for Daxxify® in China



Daxxify



Profhilo



Revanesse

Medical Devices - Intuitive Fosun

Localization

- The Shanghai Manufacturing R&D Center was put into operation in June 2024
- The largest integrated **R&D, manufacturing, and training facility** for Intuitive Surgical in Asia-Pacific region



Capacity meet the market demand

Accelerating the process of localization

- **Domestically produced Da Vinci System** entered **commercialization** in December 2023
- **Ion production capacity** manufactures biopsy needles, rotary joints and vision converters



Doctors Training 4,000+ per year

Da Vinci Surgical System

- Operating theater size **550+ m²**
- **10** simultaneous Da Vinci surgical training

Ion Robotic Bronchoscopy

- **1 CT room**
- **3 interventional rooms**
- Provide realistic clinical simulation environments and training programs for **respiratory and thoracic surgery**

Main Products

Da Vinci Surgical System

- **29** Da Vinci Surgical Systems were installed in China in 1H25
- As of June 2025, **450+** systems installed in **370** hospitals, and served **760,000+** patients
- As of June 2025, **10,488** systems were installed worldwide



Ion Robotic Bronchoscopy

- In March 2024, Ion System was approved by the NMPA for **lung cancer early diagnosis and treatment** through a minimally invasive procedure; as of June 2025, installed **6** systems and served **200+** patients
- With shape sensing technology, Ion system can operate **precise diagnostics and treatment** on peripheral lung lesions through the bronchus



Da Vinci SP surgical system

- Leveraging the "**licensed medical devices**" permission in Hainan, Da Vinci SP surgical system has achieved broad clinical application across multiple disciplines at Ruijin-Hainan Hospital. Real-world study reports have been completed in several specialties, which are expected to **accelerate its formal registration and approval process**







Healthcare Services

Healthcare Service - Performance


Segment Revenue¹



Segment Result^{1,2}



Segment Profit



Note¹: 1) Impact of medical pricing adjustments and centralized procurement, 2) increase in fixed asset depreciation due to the transfer of certain projects under construction to fixed assets, 3) higher initial fixed expenses from the launch of trial operations and the establishment of multiple rehabilitation medical institutions

Note²: segment results are obtained as segment revenue less costs of sales, selling and distribution expenses, administrative expenses and R&D expenses

Healthcare Services - Fosun Health

- Fosun Health ranked 2nd in the “2025 Top 100 Social Medical Hospital Groups” of Asclepius
- As of June 2025, Fosun health had a total of 6,600 authorized beds, and held 9 internet hospital licenses.

Hospitals in the Greater Bay Area

- Set up the “Greater Bay Area General Hospital” management mechanism to promote the integrated operation of 4 medical institutions in the areas of regional network expansion, medical discipline construction, financial operation, smart medical coverage, brand strategy improvement, supply chain efficiency enhancement and other aspects



- Class III General Hospital with 1,750 beds
- Ranked 1st in “non-public hospital in China” for 8 consecutive years
- Fosun Pharma currently holds 87.41% of the share



- | | | |
|--|--|---|
| <ul style="list-style-type: none"> Class III General Hospital with 600 beds Holds 60% of the share | <ul style="list-style-type: none"> Class III General Hospital with 800 beds Holds 70% of the share | <ul style="list-style-type: none"> Class II General Hospital with 200 beds |
|--|--|---|

AI-driven Healthcare Services


- Enhanced the ‘Cloud HIS’ smart medical cloud platform and internet hospital SaaS across multiple institutions, accelerating the online–offline integrated service model of regional medical alliances, while expanding hospital departments and patient coverage

Rehabilitation Medical Institution

- Accelerating the establishment and commencement of operations in core areas such as municipalities directly under the central government, new first-tier cities and provincial capitals
- Further developed the rehabilitation medical business and accelerated the divestment of non-core assets to optimize its asset structure.
- Operated a total of 16 rehabilitation medical institutions, of which 4 were in trial operation, with another 7 institutions under construction
- Standardized operating and management system, strengthening subspecialties such as neurerehabilitation, critical care rehabilitation and orthopaedic rehabilitation and actively developing subspecialties with competitive advantages, including pain rehabilitation, respiratory rehabilitation and traditional Chinese medicine rehabilitation
- Exploring diversified payment solutions, collaborating with insurers, and providing patients with more convenient, flexible payment channels



Sinopharm Performance







- **The pharmaceutical distribution segment** recorded revenue of **RMB 218.527 billion (-3.52% YoY)**, but **+ 0.3% compared with the second half of 2024**. Accurately captured terminal market drug-use trends, effectively adjusted its product mix, actively increased the market share of volume-based procurement and national reimbursement drugs, strengthened communication and collaboration with upstream suppliers, and enhanced product acquisition capabilities
- **The medical device distribution segment** reported revenue of RMB 57.053 billion (-2.46%YoY), mainly due to the incomplete release of hospitals' "old-for-new" equipment tender demand, the Company's continued strengthening of risk control and compliance management, and the price reductions of products under centralized volume-based procurement
- **The retail pharmacy segment** achieved counter-trend growth, with revenue reaching **RMB 17.162 billion (+3.65% YoY)**. In 1H25, despite a revenue decline at Guoda Drugstore due to the combined impact of market environment and competitive landscape, existing stores still outperformed the market in growth

Appendix



Appendix - Core Innovative Products Launched (1/4)

No.	Therapeutic Area	Product Name	Product Description	Whether is included in the NRDL	Photo of product
1	Anti-tumor and immune modulation	Han Li Kang (rituximab injection)	This drug was approved for launch by the NMPA in February 2019, and is the first domestic biosimilar. Its approved indications include: non-Hodgkin's lymphoma, chronic lymphoblastic leukaemia, rheumatoid arthritis (RA) indication. It is also the first rituximab approved for rheumatoid arthritis (RA) indication in China.	Yes	
2		Han Qu You (trastuzumab injection)	This drug is the first trastuzumab biosimilar approved for launch in China, and also the domestic monoclonal antibody biosimilar approved by China, Europe and the United States. As at the end of the Reporting Period, this drug has been approved for launch in more than 50 countries and regions, including China, Europe, the United States, Australia and Canada. The drug's trade name in EU: Zercepac, the trade name in the United States: HERCESSI™, and the trade name in Canada: Adheroza. Its approved indications include: HER2 positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer.	Yes	
3		Han Si Zhuang (serplulimab injection)	This drug (anti-PD-1 monoclonal antibody) was approved for launch by the NMPA in March 2022, and is the first innovative monoclonal antibody independently developed by the Group. In February 2025, the drug was approved by the EC, making it the first anti-PD-1 monoclonal antibody approved in the EU for the treatment of extensive-stage small cell lung cancer (ES-SCLC). The drug's trade name in the EU: Hetronify®. Its approved indications include: first-line treatment of squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ESSCLC), esophageal squamous cell carcinoma (ESCC) and non-squamous non-small cell lung cancer (nsNSCLC). It is the first anti-PD-1 monoclonal antibody drug approved for the firstline treatment of small cell lung cancer in the world. It has been recommended by guidelines including CSCO Guidelines on Small Cell Lung Cancer Treatment, CSCO Guidelines on Non-Small Cell Lung Cancer Treatment, CSCO Guidelines on Esophageal Cancer Treatment, CSCO Guidelines on Colorectal Cancer Treatment and CSCO Guidelines on Clinical Application of Immune Checkpoint Inhibitors.	No	
4		Fu Mai Ning (lucvetmetinib tablets)	This drug (a selective MEK1/2 inhibitor) was approved for launch by the NMPA in May 2025 and is classified as a class 1 new drug in China. It is the first and currently the only targeted therapy in Chinese mainland approved for both of the following indications. The approved indications include treatment for: (1) adult patients with Langerhans cell histiocytosis (LCH) and histiocytic neoplasms; (2) pediatric and adolescent patients aged 2 years and above with symptomatic, inoperable plexiform neurofibromas (PN) associated with type 1 neurofibroma (NF1).	No	
5		Fu Tuo Ning (fovinaciclib citrate capsules)	This drug (an innovative small-molecule CDK4/6 inhibitor) was approved for launch by the NMPA in May 2025 and is classified as a class 1 new drug in China. It is an orally administered, potent, highly selective small-molecule drug with a novel structure, and was included in the National Science and Technology Major Project for "Significant New Drug Development" in 2018. The approved indication is in combination with Fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer whose disease has progression after prior endocrine therapy.	No	







Appendix - Core Innovative Products Launched (2/4)

No.	Therapeutic Area	Product Name	Product Description	Whether is included in the NRDL	Photo of product
6	Anti-tumor and immune modulation	Han Da Yuan (adalimumab injection)	This drug was approved for launch by the NMPA in December 2020, and is the first domestic adalimumab biosimilar with GMP certified production base approved by both China and Europe. Its approved indications include: rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, etc..	Yes	
7		Han Bei Tai (bevacizumab injection)	This drug was approved for launch by the NMPA in November 2021. Its approved indications include: metastatic colorectal cancer, advanced, metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian cancer, etc..	Yes	
8		Yi Kai Da (Axicabtagene Ciloleucel injection)*	This product was approved for launch by the NMPA in June 2021, and is the first CAR-T cell therapy product approved for domestic launch. Its approved indications include: adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after prior second-line or higher systemic therapy, adults patients with large B-cell lymphoma (r/r LBCL) refractory to first-line immunochemotherapy or relapsing within 12 months of first-line immunochemotherapy (conditional approved). As at the end of the Reporting Period, this product has been included in over 110 urban customized commercial health insurances and over 90 commercial insurances, while the number of treatment centers on record exceeded 200, covering more than 28 provinces and municipalities across China.	No	
9		Akynzeo (netupitant and palonosetron hydrochloride capsules)*	This drug was approved for launch by the NMPA in August 2019, and is the world's first dual-channel fixed-dose combination oral compound preparation that simultaneously blocks both NK-1 receptors and 5-HT3 receptors. Its approved indication is prevention of acute and delayed nausea and vomit arising from highly emetogenic chemotherapy in adult patients.	Yes	
10		Pei Jin (telpegfilgrastim injection)*	This drug (new generation of long-lasting recombinant human granulocyte colonystimulating factor product) was approved for launch by the NMPA in June 2023, and is classified as class 1 new drug in China. Its approved indication is reduction of occurrence of infections expressed in form of febrile neutropenia in patients with nonmyeloablative cancer when receiving myelosuppression anti-tumor drug treatment which can easily cause febrile neutropenia.	Yes	
11		Fu Ke Shu® (anti-human T-lymphocyte rabbit immunoglobulin) *	The product is a polyclonal antibody inhibitor. Its approved indications include the prevention of acute transplant rejection in patients receiving solid organ transplantation (SOT) and the treatment of acute rejections if the therapeutic effect of corticosteroid treatment has proven to be unsatisfactory	Yes	

Appendix - Core Innovative Products Launched (3/4)

No.	Therapeutic Area	Product Name	Product Description	Whether is included in the NRDL	Photo of product
12	Anti-tumor and immune modulation	Su Ke Xin (avatrombopag maleate tablets)*	This drug was approved for launch by the NMPA in April 2020, and is the first oral drug approved for the treatment of thrombocytopenia related to chronic liver diseases in the world. Its approved indications include the selective thrombocytopenia treatment of adult patients with chronic liver disease (CLDT) undergoing diagnostic procedures or surgery and adult patients with chronic primary immune thrombocytopenia (ITP) who have previously responded poorly to treatments such as glucocorticoids and immunoglobulins.	Yes	
13		Otezla (apremilast tablets)*	This drug was approved for launch by the NMPA in August 2021, and is the world's first oral phosphodiesterase-4 (PDE4) inhibitor for the treatment of plaque psoriasis. Its approved indication is treatment for adult patients with moderate to severe plaque psoriasis who are suitable for phototherapy or systematic treatment.	Yes	
14		Han Nai Jia (neratinib maleate tablets)*	This drug is an oral small-molecule pan-HER tyrosine kinase inhibitor (TKI) and was approved for launch by the NMPA in June 2024. Its approved indication is intensive adjuvant therapy of human epidermal growth factor receptor-2 (HER2) positive early breast cancer in adult patients after adjuvant therapy containing trastuzumab.	Yes	
15	Metabolism and alimentary system	Atomolan (preparations for glutathione series)	This series include Atomolan (glutathione tablets) and Atomolan (glutathione for injection), both of them are class B drug under National Medical Insurance Drugs Catalogue and the basic medicine for liver diseases. In particular, Atomolan (glutathione tablets) are the first glutathione oral preparations in China, while Atomolan (glutathione for injection) is the first generic drug of its kind in China.	Yes	
16		Pang Bi Fu (etelcalcetide hydrochloride injection)*	This drug (new generation of calcimimetic) was approved for launch by the NMPA in May 2023. Its approved indication is treatment of secondary hyperparathyroidism (SHPT) of adult patients receiving hemodialysis treatment for chronic kidney disease (CKD).	No	
17		Bei Wen (keverprazan hydrochloride tablets)*	This drug (potassium ion competitive acid blocker (P-CAB)) was approved for launch by the NMPA in February 2023 and is classified as class 1 new drug in China. It is the first approved P-CAB with DU/RE double indications in China. Its approved indications include duodenal ulcer (DU), reflux esophagitis (RE), and eradication of Helicobacter pylori (H. pylori) in combination with appropriate antibiotics.	Yes	
18		Tenapanor® (tenapanor hydrochloride tablets)*	This drug (phosphate absorption inhibitor) was approved for launch by the NMPA in February 2025. It is currently the first and only phosphate absorption inhibitor approved in the world. Its approved indication is serum phosphorus level control in adult dialysis patients with chronic kidney disease (CKD) who exhibit inadequate or intolerant efficacy of phosphorus binders.	No	

Appendix - Core Innovative Products Launched (4/4)

No.	Therapeutic Area	Product Name	Product Description	Whether is included in the NRD	Photo of product
19	Anti-infection	Antimalarial series such as artesunate	This series include Artesun and Argesun (artesunate for injection), SPAQ-CO (sulfadoxine pyrimidine dispersible tablets + amodiaquine dispersible tablets) and the D-ARTEPP series (dihydroartemisininpiperazine phosphate tablets) etc. In particular, artesunate is the first class 1 new drug in China. As at the end of the Reporting Period, the Group has a total of 37 antimalarial drugs (including APIs and preparations) with WHO PQ. The second generation of artesunate for injection (Argesun) was registered and approved in 25 countries. As at the end of the Reporting Period, the Group has supplied over 420 million doses of artesunate for injection across the world.	Some of products launched in the Chinese mainland are included	
20	Cardiovascular system	Heparin series preparations	该This series include enoxaparin sodium injection, heparin sodium injection, low molecular weight heparin for injection and nadroparin calcium injection etc. Heparin series preparations are mainly used for the prevention of thrombosis or treatment of embolism. The Group has the full industry chain supply capability for low-grade and high-grade heparin products, low-molecular heparin raw materials and preparations, and the sales network covers China, the United States, South America, Europe, the Middle East and Southeast Asia.	Some of products launched in the Chinese mainland are included	
21		Yi Xin Tan (sacubitril valsartan sodium tablets)*	The drug was approved for launch by the NMPA in August 2023, and is a first-line drug for the treatment of heart failure and hypertension in an innovative crystalline form. Its approved indication is the treatment of essential hypertension. It can also be used in adult patients with chronic heart failure (NYHA class II-IV, LVEF≤40%) with reduced ejection fraction to mitigate risks of cardiovascular death and hospitalisation for heart failure.	Yes	
22	Rabies prophylaxis	Rabies vaccine (Vero cell) for human use, rabies vaccine (Vero cell) for human use (freeze dried)	Rabies vaccine (Vero cell) for human use and rabies vaccine (Vero cell) for human use (freeze dried) were approved for launch by the NMPA in September 2016 and March 2024, respectively. The approved indication is rabies prophylaxis. CTN-1V strain was used as its virus strain for production, whose gene sequence is closer to that of the street strain of prevailing rabies virus, and has better immune protection effect.	Rabies vaccine (Vero cell) for human use is included	
23	Influenza prophylaxis	Influenza virus lysate vaccine	Influenza virus lysate vaccine includes adult dosage form and paediatric dosage form. The adult dosage form was approved for launch by the NMPA in November 2005, with a specification of 0.5ml/vial in pre-filled form; and the paediatric dosage form was approved for launch by the NMPA in July 2009, with a specification of 0.25ml/vial in pre-filled form. The approved indication is prevention of influenza caused by a parent strain of virus. The product is made from influenza A1, influenza A3 and influenza B virus strains as recommended by the WHO and approved by the NMPA. The product contains more active ingredient haemagglutinin than the standard required by the Chinese Pharmacopoeia to ensure its effectiveness.	No	
24	Other	DAXXIFY® (botulinum toxin type A for injection)*	DaxibotulinumtoxinA-lanm was approved for launch by the NMPA in September 2024. The approved indications are for the temporary improvement in the appearance of moderate to severe glabellar lines in adults caused by corrugator and/or procerus muscle activity and the treatment for cervical dystonia in adults.	N/A	

Note: * License in Products

Pharma Key Progress - Products Sales over RMB100 million

2024 Sales (RMB million)	#	Formulation / Series
>1,000	4	<ul style="list-style-type: none"> Han Qu You (trastuzumab injection), Han Li Kang (rituximab injection), Han Si Zhuang (serplulimab injection), Heparin series preparations
500 -1,000	3	<ul style="list-style-type: none"> Antimalarial series such as artesunate, You Li Tong (febuxostat tablets), Su Ke Xin (avatrombopag maleate tablets)
300 - 500	4	<ul style="list-style-type: none"> Cravit (levofloxacin tablets), Atomolan (glutathione tablets), Yi Kai Da (ejilunsai injection), Akynzeo (netupitant and palonosetron hydrochloride capsules)
100 – 300	38	<p>38 varieties including</p> <ul style="list-style-type: none"> Otezla (apremilast tablets), Han Da Yuan (adalimumab injection), Han Bei Tai (bevacizumab injection), Qi Wei (quetiapine fumarate tablets), Fu Ke Shu (anti-human T-lymphocyte rabbit immunoglobulin), Yi Xin Tan (sacubitril valsartan sodium tablets), Pei Jin (telpegfilgrastim injection)

In 2024, a total of 49 formulations or product series in the pharmaceutical segment achieved sales exceeding RMB 100 million.



Han Si Zhuang (Serplulimab Injection)

- 2025 1H revenue RMB 598 million



Han Qu You (Trastuzumab Injection)

- 2025 1H revenue RMB 1,444 million



Axicabtagene Ciloleucel

- Approved 2L r/r LBCL in June 2023
- Benefited over 1000 patients since approval in 2021



Akynzeo (netupitant and palonosetron Hydrochloride capsules)

- Approved in August 2019

Large Molecules Pipeline (1/2)

Product			Target/MOA	Indication	Pre-Clinical	IND	Phase 1	Phase 2	Phase 3	NDA	
Anti-tumor	HLX10 [^] (Serplulimab)	+ Chemo	PD-1	Extensive-stage small cell lung cancer	Ongoing U.S. bridging study; approved in the EU in February 2025; granted the Orphan-drug Designation by the FDA and EC; approved in Chinese Mainland in January 2023						
				Neo-/adjuvant treatment of gastric cancer							
		+ Chemo + Radio	PD-1	Limited-stage small cell lung cancer	Ph3 global MRCT						
		+ Bevacizumab	PD-1+VEGF	Metastatic colorectal cancer	Ph3 global MRCT						
		+ HLX07	PD-1+EGFR	Squamous-cell carcinoma of the head and neck							
				Squamous non-small cell lung cancer							
	HLX07		EGFR	Solid tumors, Locally advanced or metastatic squamous cell skin cancer							
	HLX53	+ Serplulimab + bevacizumab	TIGIT+PD-1+VEGF	1L treatment of locally advanced or metastatic hepatocellular carcinoma (HCC)							
	HLX22 [#]	+ Trastuzumab + Chemo	HER2+HER2	HER2-positive locally advanced or metastatic gastroesophageal junction and gastric cancer (GC)	Ph3 global MRCT						
		+ Serplulimab + Standard Treatment (Trastuzumab + Chemo)	HER2+PD-1+HER2	HER2-positive advanced gastric cancer (GC)							
		+ Standardized Treatment (Trastuzumab + Chemo) / Deruxtecan	HER2+HER2	HER2-low, HR + locally advanced or metastatic breast cancer							
	HLX11 (Pertuzumab) [^]		HER2	Neo-/adjuvant treatment of breast cancer	BLA approved by the FDA in Feb.; BLA approved by the EMA in March; ; filed in China						
	HLX05 (Cetuximab) [^]		EGFR	Metastatic colorectal cancer and squamous-cell carcinoma of the head and neck							
	HLX13 (Ipilimumab) [^]		CTLA-4	Note ¹ Liver cancer							
	HLX15 (Daratumumab) [^]		CD38	Multiple myeloma (MM)							
HLX17 (Pembrolizumab)		PD-1	Note ²								
FS-1502 [#]	-	HER2 ADC	HER2-positive locally advanced or metastatic breast cancer								

Note: updated till the end of August 2025; Note[#]: License-in products; Note[^]: License-out products; Note¹: Melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma and esophageal squamous cell carcinoma; Note²: Melanoma, non-small cell lung cancer, esophageal cancer, head and neck squamous cell carcinoma, etc.

Large Molecules Pipeline (2/2)

Product			Target/MOA	Indication	Pre-Clinical	IND	Phase 1	Phase 2	Phase 3	NDA	
Anti-tumor	HLX42		EGFR ADC	Advanced/metastatic solid tumor	Approved clinical trials by the FDA						
	HLX43	-	PD-L1 ADC	Advanced/metastatic solid tumor	Approved clinical trials by the FDA						
				Advanced NSCLC							
			+Serplulimab	PD-1+PD-L1 ADC	ESCC						
					Advanced/metastatic solid tumor						
	HLX26	+ Serplulimab + Chemo	LAG-3 + PD-1	Advanced non-small cell lung cancer							
	VT-101 Injection		Oncolytic Virus	Solid tumours such as advanced squamous-cell carcinoma of the head and neck melanoma and breast cancer	Approved clinical trials by the FDA						
	Axicabtagene Ciloleucel		CD19	r/r iNHL	Bridging Clinical Trials in China						
	FKC889		CD19	Adult r/r ALL	Bridging Clinical Trials in China						
				Adult r/r MCL	Bridging Clinical Trials in China						
GCK-01		CD20	Relapsed or chemotherapy-resistant follicular lymphoma								
Blood System	Rabbit Anti-Human T-Lymphocyte Immunoglobulin		-	Prevention of graft-versus-host disease (GvHD) after haematopoietic stem cell transplantation							
Metabolism and Alimentary System	Mixed Protamine Zinc Recombinant Insulin Lispro Injection (25R)		INSR	Diabetes							
	Liraglutide Injection		GLP-1	Diabetes							
	Semaglutide		GLP-1	Diabetes							
	Degu Insulin Injection		INSR	Diabetes							
Others	HLX04-O^		VEGF	Wet age-related macular degeneration	Ph3 global MRCT; filed NDA in China						
	HLX14 (Denosumab)^		RANKL	Osteoporosis	Approved in the U.S. in August						
	HLX6018		GARP/TGF-β1	Idiopathic pulmonary fibrosis							
	HLX79(Human Sialidase Fusion Protein)	+Serplulimab	-	Active phase glomerulonephritis							
	LBP-SHC4		Live Biological Therapy Products	Androgenetic Alopecia (AGA)	Approved clinical trials by the FDA						

Small Molecules Pipeline (1/2)

Product		Target/MOA	Indication	Pre-Clinical	IND	Phase 1	Phase 2	Phase 3	NDA
Anti-tumor	FCN-437c		CDK4/6	Breast cancer (1L)	NDA accepted by the NMPA in Jan.				
	SAF-189		ALK/ROS1	Non-small cell lung cancer (ALK+)	NDA accepted by the NMPA in March; Approved clinical trials by the FDA				
	HLX208 [#]	-	BRAF	Solid tumors (metastatic colorectal cancer, non-small cell lung cancer, etc.) LCH and ECD					
		+Serplulimab	BRAF+PD-1	BRAF V600E or BRAF V600 mutation-positive advanced solid tumours (NSCL)					
	Luvometinib Tablets (FCN-159)		MEK1/2	Neurofibromatosis type I (Adult)					
				Low-grade glioma					
				Langerhans cell histiocytosis in children					
	FCN-338	+Chemo/ Azacitidine	BCL-2	Myeloid malignancy					
		-		Hematological malignancy	Ph3 global MRCT				
		-		Relapsed or refractory B-cell lymphoma	Ph3 global MRCT				
	XS-03	+Chemo± Bevacizumab	PLK1±VEGF	RAS mutated metastatic mCRC					
	XS-02		CHK1	Advanced solid tumors					
	XS-04		IRAK4/BTK	Malignant tumours of the haematological system					
	HLX78 [#]		SERM	Breast Cancer	Ph3 global MRCT				






Note: updated till the end of August 2025; Note[#]: License-in products; Note[^]: License-out products

Small Molecules Pipeline (2/2)


	Product	Target/MOA	Indication	Pre-Clinical	IND	Phase 1	Phase 2	Phase 3	NDA
Blood System	SBK010 Oral Solution [#]	-	Mild to moderate acute ischemic stroke						
Infectious Diseases	OP0595 (Nacubactam) [#] + Cefepime or Aztreonam	-	Infections caused by aerobic gram-negative bacteria in adults with limited treatment options						
Nervous System	Opicapone Capsule [#]	COMT	Parkinson's diseases						
	AR1001 [#]	PDE5	Alzheimer's Disease						
Vaccine	PCV24		Preventing Pneumococcal Disease						
Others	Fortacin Spray [#] (Lidocaine Prilocaine Spray)	-	Premature ejaculation						
	ET-26	-	Anesthesia						
	Luvometinib Tablets (FCN-159)	MEK1/2	Arteriovenous malformation						
	FXS6837 [^]	-	Glomerular diseases associated with abnormal complement activation such as IgA nephropathy	Ph1 Clinical Trial in Australia					
			Paroxysmal sleep haemoglobinuria (PNH)						
	XH-S004 [^]	DPP1	Non-cystic fibrosis bronchiectasis						
			COPD						
	HLX99	-	ALS	IND approved in the U.S.					
	FCN-338	BCL-2	Systemic Light Chain Amyloidosis						

Note: updated till the end of August 2025; Note[#]: License-in products; Note[^]: License-out products

Pharma - Core Products

Core Therapeutic Area	Core Products
 Anti-tumor and Immune Modulation	<p>Han Qu You (trastuzumab injection and trastuzumab drug substance), Han Li Kang (rituximab injection), Han Si Zhuang (serplulimab injection), Yi Kai Da (ejilunsai injection), Akynzeo (netupitant and palonosetron hydrochloride capsules), Pei Jin (telpegfilgrastim injection), Han Bei Tai (bevacizumab injection), Kai Lai Zhi (epinastine hydrochloride capsules), Han Nai Jia (neratinib maleate tablets), Ke Sheng (Xihuang capsules), Su Ke Xin (avatrombopag maleate tablets), Han Da Yuan (adalimumab injection), Fu Ke Shu (anti-human Tlymphocyte rabbit immunoglobulin), Otezla (apremilast tablets), Zhao Hui Xian (bicalutamide tablets), ondansetron, Tu Mei Si (pemetrexed disodium for injection), paclitaxel, Di Kai Mei (sorafenib tosylate tablets), oxaliplatin and Fu Mai Ning (lurvometinib tablets).</p>
 Metabolism and Alimentary System	<p>Atomolan (glutathione tablets), You Li Tong (febuxostat tablets), Ke Yi (new compound aloe capsules), Bei Wen (keverprazan hydrochloride tablets), animal insulin and its preparations, Atomolan (glutathione for injection), Wan Su Jing (empagliflozin tablets), Yi Bao (recombinant human erythropoietin for injection (CHO cells)), Li Qing (alfacalcidol tablets), Pu Rui Ni (pretomanid tablets), Wan Su Ping (glimepiride tablets), human insulin and its preparations, Bei Yi (potassium chloride granules) and Pang Bi Fu (etelcalcetide injection)</p>
 Anti-infection	<p>antimalarial series such as artesunate, Cravit (levofloxacin tablets), rabies vaccine (Vero cell) for human use (freeze dried), Cravit (levofloxacin injection), Pai Shu Xi Lin (piperacillin sodium and tazobactam sodium for injection), daptomycin, caspofungin, antituberculosis series, He Pu Ding (lamivudine tablets), Qiang Shu Xi Lin/Qin Shu/Er Ye Qin (piperacillin sodium and sulbactam sodium for injection), micafungin, Sha Duo Li Ka (potassium sodium dehydroandrographolide succinate for injection), vancomycin, Xi Chang/Bi Li Shu (cefmetazole sodium for injection), Er Ye Bi (ceftizoxime sodium for injection), Sai Fu Nuo (cefminox sodium for injection), Si Ke Ni (azithromycin capsules), rabies vaccine (VERO cell) for human use (non-freeze dried), Comirnaty (mRNA COVID-19 vaccine), Jie Bei An (azvudine tablets) and Ka Di (flucloxacillin sodium for injection).</p>
 Central Nervous System	<p>Qi Wei (quetiapine fumarate tablets), Ao De Jin (deproteinised calf blood serum injection), lorazepam tablets, Chang Tuo Ning (penehyclidine hydrochloride injection), dexmedetomidine, Qi Cheng (escitalopram oxalate tablets) and rocuronium bromide</p>
 Cardiovascular System	<p>Yi Xin Tan (sacubitril valsartan sodium tablets), Bang Tan (telmisartan tablets), Ya Ni An (amlodipine besilate tablets), Ke Yuan (calcium dobesilate capsules), Bang Zhi (pitavastatin calcium tablets), Xin Xian An (meglumine adenosine cyclophosphate for injection), You Di Er (alprostadiol dried emulsion for injection), Su Ka Xin (indapamide tablets) and propranolol hydrochloride injection</p>
APIs and Intermediates	<p>amino acid series, tranexamic acid, levamisole hydrochloride and clindamycin hydrochloride</p>

Pharma - Global Commercialization System



Products Selected in Volume Based Procurement (1/2)

VBP	Product	Indication	Specification	Company
4+7 scope expansion	AmlodipineBesylateTablets	High blood pressure	5mg	Yao Pharma
	Escitalopram oxalate Tablets	Depression disorder	10mg	Dongting Pharma
	Azithromycin Capsules	Infection	250mg	Erye Pharma
2 nd Round	Clindamycin Hydrochloride Capsules	Infection caused by susceptible strains such as streptococci, staphylococci and anaerobic bacteria	150mg	Yao Pharma
	Indapamide Tablets	Essential hypertension	2.5mg	Yao Pharma
	Isoniazid tablets	Tuberculosis	100mg	Hongqi Pharma
3 rd Round	Febuxostat Tablets	Long-term treatment of gout patients with hyperuricemia	40mg	Fosun Wanbang
	Quetiapine Fumarate Tablets	Manic episodes of schizophrenia and bipolar disorder	100mg	Dongting Pharmaceutical
	Pitavastatin Calcium Tablets	Hypercholesterolemia and familial Hypercholesterolemia	1mg/2mg	Fosun Wanbang
	Ethambutol Hydrochloride Tablets	Tuberculosis	250mg	Hongqi Pharma
	Memantine Hydrochloride Tablets	Moderate to severe Alzheimer's dementia	10mg	Dongting Pharmaceutical
4 th Round	Telmisartan Tablets	Essential hypertension	40mg	Fosun Wanbang
	Empagliflozin Tablets	Type 2 diabetes	10mg	Fosun Wanbang
	Calcium Dobesilate Capsules	Note 1	500mg	Zhaohui Pharma
	Sorafenib Tosylate Tablets	Inoperable or distant metastasis of hepatocellular carcinoma	200mg	Yao Pharma
	Duloxetine Hydrochloride Enteric Capsules	Generalized anxiety disorder and depression	20mg	Yao Pharma
5 th Round	Pyrazinamide Tablets	Tuberculosis	250mg	Hongqi Pharma
	Alfacalcidol Tablets	Note 2	0.25µg	Yao Pharma
	Bicalutamide	Advanced prostate cancer	50mg	Zhaohui Pharma
6 th Round	Human Insulin Injection	Diabetes	10ml: 400 unit/ 3ml: 300 unit (refill)	Fosun Wanbang
	Protamine Recombinant Human Mixed Insulin Injection (30/70)	Diabetes	3ml: 300 unit (refill)	Fosun Wanbang

Note¹: 1. diabetes-induced retinopathy; 2. heart, brain and kidney diseases caused by microcirculation disorders, such as glomerular arteriosclerosis, etc.; 3. reduce blood viscosity; 4. prevent the formation of micro-thrombosis; 5. numbness and pain in the limbs, itchy skin; 6. varicose veins and other syndromes

Note²: Improvement of symptoms caused by abnormal vitamin D metabolism in patients with chronic renal insufficiency, hypoparathyroidism, and vitamin D-resistant rickets/osteomalacia; osteoporosis

Products Selected in Volume Based Procurement (2/2)

VBP	Product	Indication	Specification	Company
7 th Round	Cefmetazole Sodium for Injection	Bacterial Infections	1g*10vials/box	Yao Pharma
	Cefminox Sodium for Injection	Bacterial Infections	0.25g*10vials/box	Yao Pharma
	Lidocaine Hydrochloride Injection	Regional anesthesia and arrhythmias	5ml:0.1g*5vials/box	Zhaohui Pharma
	Roxithromycin Tablets	Bacterial Infections	150mg*6tablets/box	Guilin Pharma
8 th Round	Enoxaparin Sodium Injection	Venous thromboembolic disease, angina pectoris, acute myocardial infarction	0.6ml	Er Ye Pharma
	Tazobactam Sodium/Piperacillin Sodium for Injection	Systemic or localised infections caused by sensitive bacteria	2.25g	Er Ye Pharma
	Oseltamivir Phosphate for oral suspension	Influenza A and B	0.36g	Er Ye Pharma
	Cefoperazone Sodium And Sulbactam Sodium for injection	Infections caused by sensitive bacteria	1g	Er Ye Pharma
	Furosemide Injection	Note ¹	2ml	Zhaohui Pharma
9 th Round	Rifampicin Capsules	Tuberculosis, leprosy, non-tuberculous mycobacterial infections	0.15g	Hongqi Pharma
	Rabeprazole Sodium Enteric-coated Tablets	Gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux oesophagitis, Zollinger-Ellison Syndrome	20mg	Yao Pharma
	Insulin			
	Insulin Lysine Injection	Diabetes	3ml:300unit(pen refills)	Fosun Wanbang
	Glycine Insulin Injection	Diabetes	3ml:300unit(pen refills)	Fosun Wanbang
10 th Round	Aspirin Enteric-coated Tablets	Unstable angina; acute myocardial infarction; prevention of recurrent myocardial infarction; post-arterial surgery or interventional procedures; prevention of cerebral infarction	100mg*14 tablets/plate × 4 plates/box	Yao Pharma
	Potassium Chloride Granules	Hypokalemia	Each bag contains potassium chloride 1.0g*6 bags/box	Yao Pharma
	Latamoxef Sodium for Injection	Various infections caused by susceptible bacteria	0.5g*1 bottle/bottle	Yao Pharma
	Ampicillin Sodium and Sulbactam Sodium for Injection	Various infections caused by susceptible bacteria	0.75g*1 bottle/bottle	Er Ye Pharma
	Piperacillin Sodium for Injection	Sepsis; various infections caused by susceptible bacteria	1g*1 bottle/box	Er Ye Pharma
	Ampicillin Sodium for Injection	Various infections caused by susceptible bacteria	1g*1 bottle/box	Er Ye Pharma
	Penicillin Sodium for Injection	Various infections caused by susceptible bacteria	800,000 units*1 bottle/bottle	Er Ye Pharma
	Sitagliptin Phosphate Tablets	Blood glucose control in patients with type 2 diabetes	100mg*30 tablets/bottle	Fosun Wanbang

Note¹: 1. oedematous diseases; 2. hypertension; 3. prevention of acute renal failure; 4. hyperkalaemia and hypercalcaemia; 5. dilutional hyponatraemia; 6. hypersecretion of antidiuretic hormone; 7. acute drug toxicosis.

免责条款及商标版权

- 本文件中所包含的所有内容(包括预测性描述),复星医药、陈述人或提供人不保证其完全准确、完整或及时,如因有关内容存在错误、遗漏或失准之处而引致的行为或结果,复星医药、陈述人或提供人对此不承担责任。
- 本文件内容不包含亦不应被视为任何投资建议,投资者基于本文件中内容做出的投资决策,责任自负。
- 本文件及其中所包含内容的所有权利包括版权均由复星医药独家所有,其中相关的“FOSUN”和“复星”字样、图案及相关LOGO标识均为复星医药合法所有的字号、商标和标识。该等资料和内容未经复星医药书面同意,任何第三方不得以包括转载在内的任何方式加以使用。
- Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.
- The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.
- Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and other related logos, like “Fosun” and “复星”, are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.

FOSUN PHARMA

复星医药

持续创新 乐享健康



复星医药微信公众号
www.fosunpharma.com